At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Levetiracetam +1 moredrug
Likely dose
Levetiracetam 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Levetiracetam 1000 mg Tablet Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Levetiracetam and Keppra® for Healthy. Completed, enrolled 30 participants across 1 site.
Detailed Summary
THe objective of this study is to compare the rate and extent of absorption of an investigational formulation of levetiracetam 1000 mg tablet to an equivalent oral dose of the commercially available reference product under fasting conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
Primary CompletionJan 2007
First PostedMar 2009
TodayJul 2026
First PostedMar 11, 2009
Enrollment StartJan 1, 2007
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.3 years ago
Interventions
Levetiracetamdrug
1000 mg Tablet
Keppra®drug
1000 mg Tablet